Nano-formulations for Ophthalmic Treatments

Main Article Content

Mahima John
Rajesh N Gacche

Abstract

Ocular disorders encompass a multitude of diseases that are unique in their cause, therapy and degree of severity. Due to distinctive morphology of the eye, efficient ocular drug delivery has proven to be a difficult task. Current treatments of ophthalmological diseases include the usage of both intrusive as well as nonintrusive methods such as injections, eye drops, ointments, gels etc. The current state of the art drug delivery methods are associated with low bioavailability and therefore nanotechnology based drug delivery approached are evolving as for improving the therapeutic index of currently used drugs against variety of ocular disorders. This review highlights the recent developments in nano-formulations for ophthalmic treatment and also offers discussions towards the future prospectus of nano-formulations in the mainstream of ophthalmic diseases.

Article Details

John, M., & Gacche, R. N. (2017). Nano-formulations for Ophthalmic Treatments. Archives of Pharmacy and Pharmaceutical Sciences, 1(1), 028–035. https://doi.org/10.29328/journal.hps.1001005
Review Articles

Copyright (c) 2017 John M, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Ann-Marie Ako-Adounvo1, Ramesh C Nagarwal, Lais Oliveira, Sai H.S. Boddu, Xiang S Wang, et al. Recent patents on ophthalmic nanoformulations and therapeutic implications. Recent Pat Drug Deliv Formul. 2014; 8: 193-201. Ref.: https://goo.gl/cnNA1Y

Carroll J, Neitz M, Hofer H, Neitz J, Williams DR. Functional photoreceptor loss revealed with adaptive optics: An alternate cause of color blindness. Proc Natl Acad Sci U S A. 2004; 101: 8461-8466. Ref.: https://goo.gl/Cm9RXU

C.P Wilkinson, Frederick L Ferris, Ronald E Klein, Paul P Lee, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology J. 2003; 110: 1677-1682. Ref.: https://goo.gl/Ft5L3J

Dyonne T Hartong, Eliot, L Berson, Thaddeus PD. Retinitis pigmentosa. The Lancet. 2006; 368: 18-24. Ref.: https://goo.gl/ErW6Yg

Kenneth P Cheng, David A Hiles, Albert W Biglan, Milton C Pettapiece. Visual Results after Early Surgical Treatment of Unilateral Conenital Cataracts. Ophthalmology J. 1991; 98: 903-910. Ref.: https://goo.gl/X6RKJF

SibelCetinel, Carlo Montemagno. Nanotechnology for the Prevention and Treatment of Cataract. Asia-Pacific J Ophthalmology. 2015; 4: 381-387. Ref.: https://goo.gl/74QdCK

Jonathan L Haines, Michael A Hauser, Silke Schmidt, William K Scott, Lana M Olson, et al. Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration. Science Journal. 2005; 308: 419-421. Ref.: https://goo.gl/boQqiH

Paul J Foster, Ralf Buhrmann, Harry A Quigley, Gordon J Johnson. The definition and classification of glaucoma in prevalence surveys. British J Opthamology. 2002; 86: 238-242. Ref.: https://goo.gl/HPTjnG

Maurice DM, Mishima. Handbook of Experimental Pharmacology. In Ocular pharmacokinetics. 1989; 57: 16-119.

Hong-Yang Zhou, Ji-Long Hao, Shuang Wang, Yu Zheng, Wen-Song Zhang. Nanoparticles in the ocular drug delivery. Int J Ophthalmol. 2013; 6: 390-396. Ref.: https://goo.gl/LatWrz

Xiaoyong Yuan, Daniela C Marcano, Crystal S Shin, Xia Hua, Lucas C Isenhart, et al. Ocular Drug Delivery Nanowafer with Enhanced Therapeutic Efficacy. J American Chemical Society. 2015; 9: 1749-1758. Ref.: https://goo.gl/XUtyUL

Bhatia S, Saurabh A. Natural Polymer Drug Delivery Systems. Springer International Publishing Switzerland. Natural Polymer Drug Delivery Systems. 2016; 1: 33-46.

Noriaki Nagai, Yoshimasa Ito. A New Preparation Method for Ophthalmic Drug Nanoparticles. Pharm Anal Acta. 2014; 5: 305. Ref.: https://goo.gl/eLQZH7

Shyam S Chaurasia, Rayne R Lim, Rajamani Lakshminarayanan, Rajiv R Mohan. Nanomedicine Approaches for Corneal Diseases. J Funct Biomater. 2015; 6: 277-298. Ref.: https://goo.gl/o7vjZs

Yuhua Weng, Juan Liu, Shubin Jin, Weisheng Guo, Xingjie Liang et al. Nanotechnology-based strategies for treatment of Ocular disease. Acta Pharm Sin B. 2017; 7; 281-291. Ref.: https://goo.gl/xZzpFG

Luu CD, Lau AM, Koh AH, Tan D. Multifocal electroretinogram in children on atropine treatment for myopia. British J Ophthalmol. 2005; 89: 151-153. Ref.: https://goo.gl/AMckhK

Marzieh Fathi, Jaleh Barar, Ayuob Aghanejad, Yadollah Omidi. Hydrogels for ocular drug delivery and tissue engineering. Bioimpacts. 2015; 5: 159-164. Ref.: https://goo.gl/PZLm1j

Vishal R Patel, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Advanced Pharmaceutical Technology & Research. 2011; 2: 81-87. Ref.: https://goo.gl/hk6GWE

Gyan P Mishra, Mahuya Bagui, Viral Tamboli, Ashim K Mitra. Recent Applications of Liposomes in Ophthalmic Drug Delivery. J Drug Delivery. 2011; 2011: 1-14. Ref.: https://goo.gl/P5EoBM

Abhirup Mandal, Rohit Bisht, Ilva D Rupenthal, Ashim K Mitra. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Controlled Release. 2017; 248: 96-116. Ref.: https://goo.gl/wXFVx4

Ammar HO, Salama HA, Ghorab, Mahmoud. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009; 10: 808-819. Ref.: https://goo.gl/Thnc6H

Frederic Lallemand, Philippe Daull, Simon Benita, Ronald Buggage, Jean-Sebastien Garrigue. Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb. J Drug Delivery. 2012; 1-16. Ref.: https://goo.gl/A1kSiu

Luigi Battaglia, Loredana Serpe, Federica Foglietta, Elisabetta Muntoni, Marina Gallarate, et al. Application of lipid nanoparticles to ocular drug delivery. Expert Opin Drug Deliv. 2016; 13: 1743-1757. Ref.: https://goo.gl/zYfRj1

Marina Kalomiraki, Kyriaki Thermos, Nikos A Chaniotakis. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. 2016; 11: 1-12. Ref.: https://goo.gl/YC8TYi

Harry A Quigley. Nanotechnology-based strategies for treatment of ocular disease. British J Opthamology. 1996; 7: 238-242.

Yuan X, Marcano DC, Shin CS, Hua X, Isenhart LC, et al. Ocular drug delivery nanowafer with enhanced therapeutic efficacy. ACS Nano. 2015; 9: 1749-1758. Ref.: https://goo.gl/H4afK3

Jiang M, Gan L, Zhu C, Dong Y, Liu J, et al. Cationic core shell lipo nanoparticles for ocular gene delivery. Biomaterials. 2012; 33: 7621-7630. Ref.: https://goo.gl/AYyRLF

Shuai Shi, Zhaoliang Zhang, Zichao Luo, Jing Yu, Renlong Liang, et al. Chitosan grafted methoxy poly(ethylene glycol)-poly(ε-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac. Sci Rep. 2015; 5: 11337. Ref.: https://goo.gl/3oZfgN

Panagiotis Mastorakos, Siva P Kambhampati, Manoj K Mishra, Tony Wu, Eric Song, et al. Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells. Nanoscale. 2015; 7: 3845-3856. Ref.: https://goo.gl/N7Aqkg

Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol. 2007; 1: 441-453. Ref.: https://goo.gl/2pkGU5

Lin HR, Sung KC. Ophthalmic drug delivery formulations and method for preparing the same. 2003.